Top

Current Oncology Reports

Published in:

01-06-2021 | Human Papillomavirus | Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Immunotherapy in Cervical Cancer

Authors: Dennis Mauricio, Burak Zeybek, Joan Tymon-Rosario, Justin Harold, Alessandro D. Santin

Published in: Current Oncology Reports | Issue 6/2021

Abstract

Purpose of Review

This review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer.

Recent Findings

There are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment.

Summary

Multiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

National Comprehensive Cancer Network, Clinical practice guidelines in oncology: cervical cancer, version 4. 2019. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. March 29 2019.

National Cancer Institute: cancer stat facts: cervix uteri cancer.https://seer.cancer.gov/statfacts/html/cervix.htm.

Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22–30. https://doi.org/10.1016/j.ajog.2015.07.022.CrossRefPubMed

Ries LAG, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975 to 2003. Bethesda: National Cancer Institute; 2006.

Surveillance, epidemiology, and end results. SEER registry data, 2000 to 2004. http://seer.cancer.gov/. Accessed 25 April 2011.

Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol. 2005;23:4626–33.CrossRefPubMed

Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009;27:4649–55.CrossRefPubMedPubMedCentral

10.

Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113–9.CrossRefPubMed

11.

Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43. https://doi.org/10.1056/NEJMoa1309748 Erratum in: N Engl J Med. 2017 Aug 17;377(7):702.CrossRefPubMedPubMedCentral

12.

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.CrossRefPubMed

13.

Varga A, Piha-Paul SA, Ott PA, et al. Pembrolizumab in patients (pts) with PD-L1-positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028. J Clin Oncol. 2017;35:abstr 5513.CrossRef

14.

Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.CrossRefPubMedPubMedCentral

15.

Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28:1594–602.CrossRefPubMed

16.••

Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470 The findings in KEYNOTE-158 led to the FDA approval of pembrolizumab for the treatment of relapsed or metastatic cervical cancer after frontline chemotherapy treatment who had tumors with PD-L1 expression.CrossRefPubMed

17.

Frenel JS, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017;35:4035–41.CrossRefPubMed

18.

Hollebecque A, Meyer T, Nadine Moore K: et al: an open-label, multicohort, phase 1/2 study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic cervical, vaginal, and vulvar cancers. Presented at American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2-6, 2017 (abstr 5504).

19.•

Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020;157(1):161–6. https://doi.org/10.1016/j.ygyno.2019.12.034This NRG-GY002 trial evaluated the activity of single agent nivolumab in persistent or recurrent cervical cancer patients. Nivolumab had acceptable safety profile but low antitumor activity in cervical cancer. Combination treatment with immune check-point inhibitors may be necessary to increase clinical responses in cervical cancer.CrossRefPubMedPubMedCentral

20.

Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020;8(2):e001126. https://doi.org/10.1136/jitc-2020-001126.CrossRefPubMedPubMedCentral

21.

Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020;30(7):1065–70. https://doi.org/10.1136/ijgc-2019-001135.CrossRefPubMedPubMedCentral

22.

Callahan MK, Wolchok JD. At the bedside: CTLA-4 and PD-1 blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41–53.CrossRefPubMedPubMedCentral

23.•

Naumann RW, Oaknin A, Meyer T, et al: Efficacy and safety of nivolumab + ipilimumab in patients with recurrent/metastatic cervical cancer. ESMO Congress 2019. Abstract LBA62. Presented September 29, 2019. This abstract reported the interim results suggesting clinical benefit from two regimens of combination nivolumab and ipilimumab for the recurrent and metastatic cervical cancer regardless of PD-L1 status.

24.

O’Malley DM, Oaknin A, Monk BJ, Leary A, Selle F, Alexandre J, et al. LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): preliminary results of two independent phase II trials. Ann Oncol. 2020;31(Supplement 4):S1164–5, ISSN 0923-7534. https://doi.org/10.1016/j.annonc.2020.08.2264.CrossRef

25.

Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). Int J Gynecol Cancer. 2020;30(1):139–43. https://doi.org/10.1136/ijgc-2019-000880.CrossRefPubMed

26.

Fujiwara K, Shapira-Frommer R, Alexandre J, Monk B, Fehm T, Colombo N, et al. 265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Ann Oncol. 2019;30(9):ix89–90 ISSN 0923-7534. https://doi.org/10.1093/annonc/mdz426.040.CrossRef

27.

Duska LR, Scalici JM, Temkin SM, Schwarz JK, Crane EK, Moxley KM, et al. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2020;126(22):4948–56. https://doi.org/10.1002/cncr.33136.CrossRefPubMed

28.

Lorusso D, Colombo N, Coleman R, et al. 164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. Int J Gynecol Cancer. 2020;30:A71.

29.

Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512–9.CrossRefPubMed

30.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.CrossRefPubMed

31.

Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett. 1981;14:227–36.CrossRefPubMed

32.

Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol Oncol Res. 2012;18:929–37.CrossRefPubMed

33.

Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, et al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol. 2019;155:144–50.CrossRefPubMedPubMedCentral

34.

Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73:2271–80.CrossRefPubMed

35.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27. https://doi.org/10.1200/JCO.2005.06.081.CrossRefPubMed

36.••

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654 This is the final analysis of GOG 240 trial, showing the addition of bevacizumab to chemotherapy resulted in significant improvements in OS and PFS compared to chemotherapy alone.CrossRefPubMedPubMedCentral

37.

Suzuki K, Nagao S, Shibutani T, Yamamoto K, Jimi T, Yano H, et al. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecol Oncol. 2019;154(3):554–7. https://doi.org/10.1016/j.ygyno.2019.05.018.CrossRefPubMed

38.

Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2011;122(3):495–500. https://doi.org/10.1016/j.ygyno.2011.05.040.CrossRefPubMedPubMedCentral

39.

Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a gynecologic oncology group study. Gynecol Oncol. 2011;121(2):303–8. https://doi.org/10.1016/j.ygyno.2011.01.030.CrossRefPubMedPubMedCentral

40.

Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, et al. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep. 2020;10(1):973. https://doi.org/10.1038/s41598-020-58009-3.CrossRefPubMedPubMedCentral

41.

Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res. 2020;26(6):1220–8. https://doi.org/10.1158/1078-0432.CCR-19-2962.CrossRefPubMed

42.

Coleman RL, Lorusso D, Gennigens C, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study. Ann Oncol. 2020;31(Supplement 4):S1162–3.CrossRef

43.

Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther. 2016;16(1):83–98. https://doi.org/10.1586/14737140.2016.1121108 Epub 2015 Dec 7.CrossRefPubMed

44.

Miles BA, Monk BJ, Safran HP. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecol Oncol Res Pract. 2017;4:9. https://doi.org/10.1186/s40661-017-0046-9.CrossRefPubMedPubMedCentral

45.

• Huh WK, Brady WE, Fracasso PM, Dizon DS, Powell MA, Monk BJ, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020;158(3):562–9. https://doi.org/10.1016/j.ygyno.2020.06.493This trial reported therapeutic vaccine, axalimogene filolisbac, in patients with progressed cervical cancer a 12-month OS of 38%, median OS of 6.1 months and median PFS of 2.8 months.CrossRefPubMedPubMedCentral

46.

Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, et al. A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018;28(4):764–72. https://doi.org/10.1097/IGC.0000000000001235.CrossRefPubMedPubMedCentral

47.

Choi YJ, Hur SY, Kim TJ, Hong SR, Lee JK, Cho CH, et al. A Phase II, Prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clin Cancer Res. 2020;26(7):1616–23. https://doi.org/10.1158/1078-0432.CCR-19-1513.CrossRefPubMed

48.

Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798–808.CrossRefPubMed

49.

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Longterm outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.CrossRefPubMedPubMedCentral

50.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–24.CrossRefPubMedPubMedCentral

51.

Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res. 2011;17:45504557.CrossRef

52.

Stevanovic S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33:1543–50.CrossRefPubMedPubMedCentral

53.

Stevanovic S, Helman SR, Wunderlich JR, et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019;25:1486–93.CrossRefPubMed

54.

Jazaeri AA, et al. Safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2019;37(15_suppl):2538.CrossRef

55.

Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200–5. https://doi.org/10.1126/science.aak9510.CrossRefPubMedPubMedCentral

Title: Immunotherapy in Cervical Cancer
Authors: Dennis Mauricio
Burak Zeybek
Joan Tymon-Rosario
Justin Harold
Alessandro D. Santin
Publication date: 01-06-2021
Publisher: Springer US
Keywords: Human Papillomavirus
Cervical Cancer
Cervical Cancer
Targeted Therapy
Bevacizumab
Cytostatic Therapy
Published in: Current Oncology Reports / Issue 6/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-021-01052-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2021

Update on Histological Reporting Changes in Neuroendocrine Neoplasms

Integrative Approaches to Minimize Peri-operative Symptoms

Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia

Correction to: Psychosocial Interventions for Pain Management in Advanced Cancer Patients: a Systematic Review and Meta-analysis

Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building

Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer